Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16.

Authors

Benjamin Ungar¹, Ana B Pavel¹, Randall Li¹, Grace Kimmel¹, John Nia¹, Peter Hashim¹, Hee Jin Kim¹, Margot Chima¹, Anjali S Vekaria¹, Yeriel Estrada¹, Hui Xu¹, Xiangyu Peng¹, Giselle K Singer¹, Danielle Baum¹, Yasaman Mansouri¹, Mark Taliercio¹, Emma Guttman-Yassky²

Affiliations

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
² Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY; Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY. Electronic address: Emma.Guttman@mountsinai.org.

PMID: 32428528
DOI: 10.1016/j.jaci.2020.04.055

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / immunology
Dermatitis, Atopic / pathology
Double-Blind Method
Drug Delivery Systems*
Female
Humans
Interleukin-17 / antagonists & inhibitors
Interleukin-17 / immunology*
Th17 Cells / immunology*

Substances

Antibodies, Monoclonal, Humanized
IL17A protein, human
Interleukin-17
secukinumab